Founded by Carolyn R. Bertozzi in 2019, Lycia Therapeutics is a Series B biotech company based in San Diego, California. The company's lysosomal targeting chimeras (LYTACs) platform can degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases, including cancers and autoimmune conditions. The LYTAC platform can target challenging membrane proteins, clear pathogenic immune complexes in circulation, and deplete antibodies to specific antigens of interest. Lycia's technology has the potential to deliver next-generation therapeutics for a variety of diseases.